IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

GRAZIOSO, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.846
NA - Nord America 7.683
AS - Asia 7.409
Continente sconosciuto - Info sul continente non disponibili 1.175
SA - Sud America 668
AF - Africa 191
OC - Oceania 40
Totale 25.012
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.339
IT - Italia 2.415
CN - Cina 2.298
SG - Singapore 1.848
GB - Regno Unito 1.682
DE - Germania 810
HK - Hong Kong 688
BD - Bangladesh 684
RU - Federazione Russa 655
SE - Svezia 589
BR - Brasile 476
IN - India 431
VN - Vietnam 385
FR - Francia 359
NL - Olanda 229
TR - Turchia 227
KR - Corea 224
CA - Canada 201
IE - Irlanda 195
JP - Giappone 192
FI - Finlandia 176
UA - Ucraina 163
ID - Indonesia 114
DK - Danimarca 106
CH - Svizzera 88
EU - Europa 79
ES - Italia 75
CI - Costa d'Avorio 67
PL - Polonia 62
MX - Messico 61
CO - Colombia 56
AR - Argentina 53
PK - Pakistan 50
AT - Austria 43
ZA - Sudafrica 41
BE - Belgio 39
IQ - Iraq 33
IR - Iran 32
AU - Australia 31
CL - Cile 29
PH - Filippine 29
EC - Ecuador 24
EG - Egitto 19
TH - Thailandia 19
BY - Bielorussia 18
GR - Grecia 18
TW - Taiwan 18
MY - Malesia 17
LV - Lettonia 16
CZ - Repubblica Ceca 15
JM - Giamaica 14
PT - Portogallo 14
RO - Romania 14
UZ - Uzbekistan 13
PR - Porto Rico 12
SA - Arabia Saudita 12
AE - Emirati Arabi Uniti 11
DZ - Algeria 11
CR - Costa Rica 10
PE - Perù 10
AL - Albania 9
MA - Marocco 9
NG - Nigeria 9
NP - Nepal 9
VE - Venezuela 9
KE - Kenya 8
NO - Norvegia 8
AZ - Azerbaigian 7
GT - Guatemala 7
JO - Giordania 7
LU - Lussemburgo 7
NZ - Nuova Zelanda 7
RS - Serbia 7
GE - Georgia 6
HN - Honduras 6
IL - Israele 6
SI - Slovenia 6
HU - Ungheria 5
OM - Oman 5
PY - Paraguay 5
SV - El Salvador 5
TT - Trinidad e Tobago 5
BG - Bulgaria 4
BO - Bolivia 4
BZ - Belize 4
CM - Camerun 4
DO - Repubblica Dominicana 4
LB - Libano 4
LK - Sri Lanka 4
LT - Lituania 4
PA - Panama 4
TN - Tunisia 4
YE - Yemen 4
BS - Bahamas 3
GA - Gabon 3
KG - Kirghizistan 3
KW - Kuwait 3
MD - Moldavia 3
MM - Myanmar 3
MO - Macao, regione amministrativa speciale della Cina 3
Totale 23.856
Salva come PNG Salva come JPEG
Città #
Southend 1.371
Singapore 1.014
Ashburn 910
Milan 821
Hong Kong 576
Dallas 477
Beijing 436
San Jose 429
Chandler 398
Council Bluffs 330
Santa Clara 303
Seattle 287
Los Angeles 237
Princeton 214
Wilmington 191
Dublin 189
Hefei 183
New York 181
Fairfield 179
Hanover 147
Ann Arbor 143
Ho Chi Minh City 125
Frankfurt am Main 120
Dearborn 118
Munich 118
Bengaluru 117
Woodbridge 113
Houston 111
Nanjing 111
Rome 111
Buffalo 110
Lauterbourg 106
Boardman 105
Guangzhou 101
Hanoi 101
Mountain View 96
Moscow 94
Shanghai 86
Jacksonville 85
Redmond 83
Helsinki 78
Redwood City 75
Jakarta 72
Cambridge 70
Abidjan 67
Naples 67
Tokyo 66
Seoul 64
Somerville 62
Hangzhou 56
Chicago 55
Jinan 55
The Dalles 54
Des Moines 53
Toronto 53
Serra 51
Columbus 50
Sakarya 47
Cangzhou 46
Istanbul 46
Andover 44
Bogotá 44
Tianjin 44
São Paulo 43
Phoenix 42
Changsha 41
Turin 40
Shenyang 39
Berlin 36
Warsaw 36
London 33
Shenzhen 33
Medford 32
Montreal 32
Florence 31
Brussels 28
Chengdu 28
Lugano 27
Amsterdam 26
Nanchang 26
Nuremberg 26
Orem 26
Eitensheim 25
Atlanta 24
San Diego 24
Haiphong 23
Hamburg 23
Fuzhou 22
Mexico City 22
Mumbai 21
Stockholm 21
Zhengzhou 21
Barcelona 20
Brooklyn 20
Lund 20
Palermo 20
Rio de Janeiro 20
Dalian 19
Johannesburg 19
Odernheim 19
Totale 13.354
Salva come PNG Salva come JPEG
Nome #
Agonisti nicotinici selettivi nel trattamento di patologie del Sistema Nervoso Centrale 621
The response of Escherichia coli biofilm to salicylic acid 565
Systematic Development of Peptide Inhibitors Targeting the CXCL12/HMGB1 Interaction 538
Structure-based drug design, synthesis and biological assays of P. falciparum Atg3-Atg8 protein-protein interaction inhibitors 496
Computationally Driven Structure Optimization, Synthesis, and Biological Evaluation of Imidazole-Based Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Inhibitors 461
PCSK9 inhibitors: a patent review 2018-2023 408
Novel tricyclic Delta(2)-isoxazoline and 3-oxo-2-methyl-isoxazolidine derivatives: synthesis and binding affinity at neuronal nicotinic acetylcholine receptor subtypes 397
Rational design of allosteric modulators of the aromatase enzyme: An unprecedented therapeutic strategy to fight breast cancer 372
Modification of the anabaseine pyridine nucleus allows achieving binding and functional selectivity for the α3β4 nicotinic acetylcholine receptor subtype [Modification of the anabaseine pyridine nucleus allows achieving binding and functional selectivity for the alpha 3 beta 4 nicotinic acetylcholine receptor subtype] 348
Exploring Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Autoproteolysis Process by Molecular Simulations: Hints for Drug Design 341
New analogues of epiboxidine incorporating the 4,5-dihydroisoxazole nucleus: Synthesis, binding affinity at neuronal nicotinic acetylcholine receptors, and molecular modeling investigations 291
Application of the Ugi reaction with multiple amino acid-derived components : synthesis and conformational evaluation of piperazine-based minimalist peptidomimetics 289
Elagolix analogues as potential new GnRH antagonists: design, synthesis and characterization 271
Lupin peptides modulate the protein-protein interaction of PCSK9 with the low density lipoprotein receptor in HepG2 cells 269
Natural compounds targeting E. Coli WRBA as antibiofilm agents: Virtual screening, design and synthesis of analogs, biological evaluation 269
Synthesis of epibatidine-related Delta(2)-isoxazoline derivatives and evaluation of their binding affinity at neuronal nicotinic acetylcholine receptors 268
Design, Synthesis, and Pharmacological Characterization of Novel Spirocyclic Quinuclidinyl-Δ2-Isoxazoline Derivatives as Potent and Selective Agonists of α7 Nicotinic Acetylcholine Receptors 263
Orthosteric and allosteric ligands selectively acting at cholinergic receptor subtypes 262
γ-HYDROXY LACTONE BASED PPARγ NON-AGONISTS AS SAFE AND INNOVATIVE ANTI-DIABETIC AGENTS 253
Molecular dynamics simulations of the Salmonella typhi Vi antigenic polysaccharide and effects of the introduction of a zwitterionic motif 251
Biological Characterization of Computationally Designed Analogs of peptide TVFTSWEEYLDWV (Pep2-8) with Increased PCSK9 Antagonistic Activity 250
Novel ligands for neuronal nicotinic receptor subtypes: synthetic, pharmacological and molecular docking studies 248
Investigation of Chlorella pyrenoidosa Protein as a Source of Novel Angiotensin I-Converting Enzyme (ACE) and Dipeptidyl Peptidase-IV (DPP-IV) Inhibitory Peptides 246
Allosteric modulation of alpha7 nicotinic receptors : mechanistic insight through metadynamics and essential dynamics 241
Synthesis, Binding Affinity at Glutamic Acid Receptors, Neuroprotective Effects, and Molecular Modeling Investigation of Novel Dihydroisoxazole Amino Acids 241
Diazabicyclo analogues of maraviroc : synthesis, modeling, NMR studies and antiviral activity 239
Synthesis of enantiomerically pure HIP-A and HIP-B and investigation of their activity as inhibitors of excitatory amino acid transporters 236
Oxidation State Dependent Conformational Changes of HMGB1 Regulate the Formation of the CXCL12/HMGB1 Heterocomplex 232
Design of novel α7-subtype-preferring nicotinic acetylcholine receptor agonists: application of docking and MM-PBSA computational approaches, synthetic and pharmacological studies 230
Determination of acid dissociation constants of compounds active at neuronal nicotinic acetylcholine receptors by means of electrophoretic and potentiometric techniques 230
Inhibition of PCSK9D374Y/LDLR Protein–Protein Interaction by Computationally Designed T9 Lupin Peptide 230
The impact of Chirality on Medicinal Chemistry 228
Engineering of α-conotoxin MII-derived peptides with increased selectivity for native α6β2* nicotinic acetylcholine receptors 228
New spirocyclic Δ2-isoxazoline derivatives related to selective agonists of α7 neuronal nicotinic acetylcholine receptors 227
Alpha7 nicotinic acetylcholine receptor agonists: prediction of their binding affinity through a molecular mechanics poisson-boltzmann surface area approach 226
Design and synthesis of selective ligands targeting different nAChR subtypes 225
γ-hidroxy-lactone derivatives as ppar-γ non-agonists blocking cdk5-mediated phosporylation for a safer anti-diabetic treatment 224
Bifunctional compounds targeting both D2 and non-α7 nACh receptors: design, synthesis and pharmacological characterization 222
Determination of acid dissociation constants of poorly water-soluble nicotinic ligands by means of electrophoretic and potentiometric techniques 222
Trans-Epithelial Transport, Metabolism and Biological Activity Assessment of the Multi-Target Lupin Peptide LILPKHSDAD (P5) and Its Metabolite LPKHSDAD (P5-Met) 221
Computational Design, Synthesis, and Biological Evaluation of Diimidazole Analogues Endowed with Dual PCSK9/HMG-CoAR-Inhibiting Activity 220
Elagolix Sodium Salt and Its Synthetic Intermediates: A Spectroscopic, Crystallographic, and Conformational Study 219
Towards a safe treatment of Insulin Resistance: γ-hydroxy lactone-based derivatives as PPARγ non-agonists 216
Design of Cyclopentaisoxazoline Amino Acids as Conformationally Constrained Agonists at Glutamate Receptors 216
COMPUTATIONAL INVESTIGATION ON SUBSTRATE UPTAKE AND RELEASE IN A GLUTAMATE TRANSPORTER 214
Isonitrile-Based Multicomponent Synthesis of β-Amino Boronic Acids as β-Lactamase Inhibitors 214
Natural and nature-inspired compounds targeting E. coli WrbA as antibiofilm agents: computational studies, synthesis, and biological evaluation 213
Synthesis of Novel N1-Substituted Bicyclic Pyrazole Amino Acids and Evaluation of Their Interaction with Glutamate Receptors 212
Computational Design and Biological Evaluation of Analogs of Lupin Peptide P5 Endowed with Dual PCSK9/HMG-CoAR Inhibiting Activity 212
In silico design of agonists targeting the alpha7 nicotinic acetylcholine receptors, their synthesis and preliminary pharmacological evaluation 207
Learning to Rank Food Images 207
Covalent docking of selected boron-based serine beta-lactamase inhibitors 206
Insights on the atropisomeric properties of elagolix and its derivatives 204
Nicotine-Modulated Subunit Stoichiometry Affects Stability and Trafficking of α3β4 Nicotinic Receptor 204
Elagolix analogues as potential new GnRH antagonists 200
Synthesis of Conformationally Constrained Glutamic Acid Homologues and Investigation of Their Pharmacological Profiles 198
Lupin LILPKHSDAD (P5) peptide is a novel bi-functional inhibitor of PCSK9, a new target for the hypercholesterolemia treatment 198
Synthesis, chiral resolution, and enantiopharmacology of a potent 2,3-benzodiazepine derivative as noncompetitive AMPA receptor antagonist 196
(-)-HIP-A and (+)-HIP-B: investigation of the pharmacological profile and potential therapeutic applications 196
Unlocking the Antibiofilm Potential of Natural Compounds by Targeting the NADH:quinone Oxidoreductase WrbA 195
Multidisciplinary strategy to investigate new lupin peptide inhibitors of PCSK9 activity as useful approach for cardiovascular disease risk reduction 192
Novel Non-peptide Uracil-derived Human Gonadotropin-Releasing Hormone Receptor Antagonists 191
Enhancing the activity of γ-hydroxy lactone derivatives as innovative peroxisome proliferator-activated receptor γ non-agonists inhibiting cyclin-dependent kinase 5-mediated phosphorylation 186
Disrupting the PCSK9/LDLR protein-protein interaction by an imidazole-based minimalist peptidomimetic 186
Mechanistic Insights into the Antibiofilm Mode of Action of Ellagic Acid 183
Synthesis of novel epibatidine-related derivatives through 1,3-dipolar cycloaddition of pyridinenitrile oxides 183
Synthesis of novel enantiopure 2-isoxazoline and 2-pyrazoline amino acids and their activity at glutamic acid receptors and transporters 181
Computational Design, Synthesis, and Biophysical Evaluation of β-Amido Boronic Acids as SARS-CoV-2 Mpro Inhibitors 180
Analytical, computational and formulation studies on TPGS as P-gp inhibitor 180
Computational approaches in the rational design of improved carbonyl quenchers : focus on histidine containing dipeptides 180
Selective nicotinic agonists to treat pathologies of the central nervous system 178
Development of a Three-Dimensional Model for the N-Methyl-D-aspartate NR2A Subunit 176
FYCO1 Peptide Analogs: Design and Characterization of Autophagy Inhibitors as Co-Adjuvants in Taxane Chemotherapy of Prostate Cancer 175
Design, synthesis, and pharmacological characterization of novel, potent NMDA receptor antagonists 174
Novel bicylic delta2-isoxazoline and 3-oxo-isoxazolidine derivatives : synthesis and binding affinity at neuronal nicotinic receptor subtypes 174
Metadynamic investigations of the aspartate binding at glutamate transporters 170
Synthesis of 3-hydroxy- and 3-carboxy-Delta(2)-isoxazoline amino acids and evaluation of their interaction with GABA receptors and transporters 169
A potent nonapeptide inhibitor for the CXCL12/HMGB1 heterocomplex: A computational and experimental approach 168
DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF PEPTIDOMIMETIC FALCIPAIN-2 INHIBITORS AS ANTIMALARIAL AGENTS 168
Modulatori Fotosensibili dell’adesione batterica: una nuova strategia per ridurre l’antibiotico-resistenza 167
A new class of GnRH receptor modulators endowed with atropisomerism 166
Mechanism of falcipain-2 inhibition by α,β-unsaturated benzo[1,4]diazepin-2-one methyl ester 164
New Hybrid and Mutant PIA and MII Toxins with Greater Affinty and Selectivity for the A6* Subtype 160
Computational Design of Novel Cyclic Peptides Endowed with Autophagy-Inhibiting Activity on Cancer Cell Lines 159
Light-Responsive Modulators of Bacterial Cell Adhesion Proteins: a Novel Strategy against AMR? 158
PCSK9-inhibiting compounds 158
Nature‐Inspired Compounds Targeting Escherichia coli WrbA as Biofilm‐Modulating Agents: Computational Design, Synthesis, and Biological Evaluation 157
Synthesis of new isoxazoline-based acidic amino acids and investigation of their affinity and selectivity profile at ionotropic glutamate receptors 156
Synthesis, chiral resolution and pharmacological evaluation of a 2,3-benzodiazepine-derived noncompetitive AMPA receptor antagonist 154
How computational chemistry and drug delivery techniques can support the development of new anticancer drugs 150
γ-HYDROXY LACTONE BASED PPARγ NON-AGONISTS AS SAFE AND INNOVATIVE ANTI-DIABETIC AGENTS. 148
Investigating the mechanism of substrate uptake and release in the glutamate transporter homologue GltPh through metadynamics simulations 142
Synthesis and Molecular Modeling Studies of Derivatives of a Highly Potent Peptidomimetic Vinyl Ester as Falcipain-2 Inhibitors 142
Alkene Epoxidations Mediated by Mn-Salen Macrocyclic Catalysts 141
Evaluation of binding free Energy of nicotinic agonists by the linear interaction energy (LIE) approach 138
Synthesis and binding affinity at neuronal nicotinic acetylcholine receptors of novel epibatidine-related delta2-isoxazoline derivatives 138
Synthesis and molecular modeling of novel dihydroxycyclopentane-carbonitrile nor-nucleosides by bromonitrile oxide 1,3-dipolar cycloaddition 133
Inactivation of TEM-1 by avibactam (NXL-104): Insights from quantum mechanics/molecular mechanics metadynamics simulations 132
Focused Design of Novel Cyclic Peptides Endowed with GABARAP-Inhibiting Activity 132
Ago-allosteric modulation of nicotinic alpha7 receptors : a mechanistic insight by metadynamics and essential dynamics 130
Totale 22.545
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.247
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.247
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.387 0 60 44 67 141 172 203 105 129 113 112 241
2022/20231.793 254 178 167 159 193 262 44 148 180 45 94 69
2023/20241.678 79 97 107 111 310 122 169 86 77 110 203 207
2024/20253.348 146 269 77 310 273 189 178 376 176 261 402 691
2025/20268.761 737 596 957 839 736 493 998 416 792 568 853 776
2026/20271.095 553 542 0 0 0 0 0 0 0 0 0 0
Totale 25.012